Melanoma | Tumor

Expert Shares Key Insights During Melanoma Awareness Month

May 9th 2025, 8:00pm

Video

For Melanoma Awareness Month, Dr. Douglas Johnson explains how stage and features of the disease can guide treatment decisions after diagnosis.

Fighting for Patients, Processes and Education

May 6th 2025, 9:00pm

Article

I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.

Immune Therapy Expands Melanoma Treatment to More Patients

May 6th 2025, 8:00pm

Video

Immune therapy is generally safer than chemotherapy, allowing more patients with melanoma and other conditions like heart or lung issues receive treatment.

AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo

April 14th 2025, 4:00pm

Article

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

April 12th 2025, 2:00pm

Article

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

What Role May ctDNA Have in Melanoma Management?

April 11th 2025, 1:00pm

Article

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.

Melanoma Taught Me Faith, Gratitude and That Nothing Is Permanent

April 10th 2025, 8:00pm

Article

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.

FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma

April 4th 2025, 4:06pm

Article

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.

First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma

March 30th 2025, 6:00pm

Article

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

March 28th 2025, 3:00pm

Article

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.